CXCL8 and inflammatory bowel disease: Interestingly, as compared healthy donors, both ADA and IFX had clearly limited efficacies in blocking TNF-mediated responses in blood of IBD patients as measured by elevated production of ICAM-1, TNF and IL-8 mRNAs (Figure 2D–F) as well as release of IL-8 in serum (Figure 2G).